News
Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionised cancer treatment, especially for aggressive and ...
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...
Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor natural ...
Researchers said they identified a particular set of adverse effects in autoimmune disease patients treated with chimeric ...
Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.
After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel ...
A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...
Recent advances in developing cellular therapies, a broad group of strategies that use cells to treat disease, have shown efficacy in some types of blood c | Cancer ...
Chimeric antigen receptor (CAR) T cells targeting CD19 ... with lymphoma after the failure of previous anti-CD19 CAR T-cell therapy. (ClinicalTrials.gov number, NCT04684563.) ...
New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...
Sarcopenia, a hallmark of cancer cachexia, is associated with poor outcomes in chimeric antigen receptor (CAR) T-cell therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results